Grace Therapeutics GRCE
NASDAQ GRCE
$1.75 -0.06 (-3.31%)
At close: Nov 16, 2026 · 4:00 PM EST

Grace Therapeutics (GRCE) Return on Capital Employed [ROCE] (2016 - 2026)

Updated

Grace Therapeutics' Return on Capital Employed [ROCE] was -45.28% in fiscal Q2 2027 (quarter ended Sep 30, 2026), down 26.60 percentage points from -18.68% a year earlier and down 3.42 percentage points from the prior quarter.

Analysis

Grace Therapeutics (GRCE) Return on Capital Employed [ROCE] (2016 - 2026) Analysis & Trends

For FY2026 (ended Mar 31, 2026), Return on Capital Employed [ROCE] at Grace Therapeutics came in at -16.49%, up 7.10 percentage points from FY2025.

  • Return on Capital Employed [ROCE] shows a five-year change of +23.48 percentage points (FY2021 to FY2026).
  • In earlier fiscal years, Return on Capital Employed [ROCE] was -23.59% in FY2025 (-6.34 pp), -17.24% in FY2024 (+34.67 pp), -51.92% in FY2023 (-35.02 pp) and -16.89% in FY2022 (+23.08 pp).
  • The fiscal Q2 2027 figure marks the lowest quarterly Return on Capital Employed [ROCE] since fiscal Q3 2024.
  • Compared with a year earlier, Return on Capital Employed [ROCE] was higher in four of the last eight quarters, with an average year-over-year change of +0.49 percentage points.
  • The best year-over-year quarter for Return on Capital Employed [ROCE] over five years was fiscal Q3 2022 (a gain of 79.76 percentage points); the worst was fiscal Q1 2024 (a drop of 56.05 percentage points).
  • Per Business Quant data, GRCE's Return on Capital Employed [ROCE] in the three fiscal quarters before Q2 2027 was -41.86% (Q1 2027), -16.93% (Q4 2026) and -16.98% (Q3 2026).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn 35.41%
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn 17.52%
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn 21.60%
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn 4.65%
5 Novartis Ag 310.90 Bn 284.14 Bn - -
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn 9.91%
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn 17.37%
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn -6.15%
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn 11.32%
10 Grace Therapeutics 35.10 Mn -35.61 Mn - -45.28%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -45.28%
Jun 30, 2026 -41.86%
Mar 31, 2026 -16.93%
Dec 31, 2025 -16.98%
Sep 30, 2025 -18.68%
Jun 30, 2025 -21.59%
Mar 31, 2025 -25.79%
Dec 31, 2024 -27.34%
Sep 30, 2024 -24.82%
Jun 30, 2024 -19.39%
Mar 31, 2024 -17.59%
Dec 31, 2023 -63.19%
Sep 30, 2023 -65.83%
Jun 30, 2023 -70.00%
Mar 31, 2023 -55.16%
Dec 31, 2022 -16.02%
Sep 30, 2022 -15.71%
Jun 30, 2022 -13.95%
Mar 31, 2022 -13.19%
Dec 31, 2021 -11.82%
API Access

Grace Therapeutics Return on Capital Employed [ROCE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=GRCE&period=max&api_key=YOUR_API_KEY